13 Best Penny Stocks to Buy According to Billionaire Ken Griffin
Yahoo FinanceApr 8 17:38 ET
Analysts' Opinions Are Mixed on These Healthcare Stocks: Kezar Life Sciences (KZR), Fisher & Paykel Healthcare Corporation Limited (OtherFSPKF) and Cue Health (HLTH)
TipRanksMar 25 08:20 ET
Kezar Life Sciences: KZR-261 Dose Escalation Study Currently Enrolling 9th Cohort>KZR
Kezar Life Sciences: KZR-261 Dose Escalation Study Currently Enrolling 9th Cohort>KZR
Dow JonesMar 14 16:06 ET
Express News | Kezar Life Sciences Q4 EPS $(0.44) Misses $(0.38) Estimate
Moomoo 24/7Mar 14 16:04 ET
Kezar Life Sciences Still Expects Topline Data From Lupus Nephritis Treatment Trial In Mid-2026>KZR
Kezar Life Sciences Still Expects Topline Data From Lupus Nephritis Treatment Trial In Mid-2026>KZR
Dow JonesMar 14 16:04 ET
Kezar Life Sciences 4Q Loss/Shr 44c >KZR
Kezar Life Sciences 4Q Loss/Shr 44c >KZR
Dow JonesMar 14 16:01 ET
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Compensation Committee of the
BusinesswireMar 8 16:05 ET
Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference
Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Chris Kirk, Co-founder and Chief
BusinesswireFeb 28 16:01 ET
Reported Late Monday, Everest Medicines And Kezar Life Sciences Received IND Approval From China's NMPA For The PALIZADE Trial In Lupus Nephritis
Everest Medicines (HKEX 1952.HK) and Kezar Life Sciences, Inc. (NASDAQ:KZR) announced today that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) approve
BenzingaFeb 27 03:13 ET
Everest Medicines and Kezar Life Sciences Receive IND Approval From China NMPA for PALIZADE Trial in Lupus Nephritis
Everest Medicines (HKEX 1952.HK) and Kezar Life Sciences, Inc. (Nasdaq: KZR) announced today that the Center for Drug Evaluation (CDE) of China's...
PR NewswireFeb 26 18:10 ET
As Oversupply Deflates Lithium Bubble, IPO Market Keeps In High Spirits
The lithium market is facing persistent turmoil as spot prices have continuously declined for more than a year. Supply shortages and speculation caused a lithium bubble in 2022, with spot prices reach
BenzingaJan 8 12:20 ET
Analysts' Top Healthcare Picks: DocGo (DCGO), Kezar Life Sciences (KZR)
TipRanksDec 4, 2023 06:30 ET
Analyst Expectations for Kezar Life Sciences's Future
Analysts have provided the following ratings for Kezar Life Sciences (NASDAQ:KZR) within the last quarter: BullishSomewhat BullishIndifferentSomewhat BearishBearishTotal Ratings30100Last 30D100001M Ag
BenzingaNov 27, 2023 09:00 ET
Kezar Life Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disor
BusinesswireNov 21, 2023 16:01 ET
Kezar Life Sciences Is Maintained at Equal-Weight by Wells Fargo
Kezar Life Sciences Is Maintained at Equal-Weight by Wells Fargo
Dow JonesNov 14, 2023 08:38 ET
Wells Fargo Maintains Equal-Weight on Kezar Life Sciences, Lowers Price Target to $2
Wells Fargo analyst Derek Archila maintains Kezar Life Sciences (NASDAQ:KZR) with a Equal-Weight and lowers the price target from $4 to $2.
BenzingaNov 14, 2023 08:29 ET
Hold Rating for Kezar Life Sciences Amid Uncertainty: An Analysis of Management Changes, Drug Trials, and Financial Prospects
TipRanksNov 14, 2023 05:47 ET
Kezar Life Sciences GAAP EPS of -$0.32 Beats by $0.04, Revenue of $7M Beats by $6.7M
Seeking AlphaNov 14, 2023 01:54 ET
Analysts Are Bullish on Top Healthcare Stocks: Antibe Therapeutics (ATBPF), Kezar Life Sciences (KZR)
TipRanksNov 13, 2023 18:30 ET
Express News | Kezar Life Sciences Q3 EPS $(0.32) Beats $(0.35) Estimate, Sales $7.00K
Moomoo 24/7Nov 13, 2023 17:14 ET
No Data
No Data